When used in combination with levodopa, COMT inhibitors have been shown to reduce the amount of “off” time experienced by patients with advanced Parkinson's disease, as well as increase the amount of “on” time and reduce the required dose of levodopa. The gene discussed is COMT; the disease is Parkinson disease.